On July 29, local time, Johnson & Johnson announced that it has signed a binding agreement with Sail Biomedicines to acquire exclusive options for Sail for US$2.58 billion. Under the terms of the agreement, Johnson & Johnson will make initial payments totaling $785 million, including an equity investment of $465 million, and additional contingent payments of up to $140 million when specific development milestones are reached. After Johnson & Johnson decides to exercise the option, Johnson & Johnson will pay an additional $2.58 billion. Assuming the option is exercised, Johnson & Johnson expects the agreement to dilute the adjusted operating earnings per share in 2026 and the adjusted earnings per share by approximately $0.18, and by approximately $1.28 in 2027.

On July 29, local time, Johnson & Johnson announced that it has signed a binding agreement with Sail Biomedicines to acquire exclusive options for Sail for US$2.58 billion. Under the terms of the agreement, Johnson & Johnson will make initial payments totaling $785 million, including an equity investment of $465 million, and additional contingent payments of up to $140 million when specific development milestones are reached. After Johnson & Johnson decides to exercise the option, Johnson & Johnson will pay an additional $2.58 billion. Assuming the option is exercised, Johnson & Johnson expects the agreement to dilute the adjusted operating earnings per share in 2026 and the adjusted earnings per share by approximately $0.18, and by approximately $1.28 in 2027.